Abstract: The present invention relates to a hemostatic absorbable composition, comprising: a flowable plurality of separate aggregates each comprising: a plurality of absorbable carrier particles coated on a surface thereof by a plurality of smaller particles comprising an absorbable supplemental hemostasis-promoting agent. In some embodiments, the absorbable carrier particles comprise gelatin or collagen, and the supplemental hemostasis-promoting agent comprises oxidized cellulose, oxidized regenerated cellulose, carboxylic oxidized cellulose, carboxylic oxidized regenerated cellulose, thrombin, or tranexamic acid.

Abstract: One embodiment of the present invention sets forth a technique for training an image classifier. The technique includes training a first vision transformer model to generate patch labels for corresponding images patches of images, converting the patch labels to token labels, and training a second vision transformer model to classify images based on the token labels.

Abstract: The present invention is directed to a hemostatic material comprising a compacted, hemostatic aggregates of cellulosic fibers. In some aspects, the hemostatic material further includes additives, such as carboxymethyl cellulose (CMC) or other polysaccharides, calcium salts, anti-infective agents, hemostasis promoting agents, gelatin, collagen, or combinations thereof. In another aspect, the present invention is directed to a method of making the hemostatic materials described above by compacting a cellulosic-based material into hemostatic aggregates. In another aspect, the present invention is directed to a method of treating a wound by applying hemostatic materials described above onto and/or into the wound of a patient.

Abstract: An electronic device includes gate lines, maintained at a low level voltage during a blank period and sequentially scanned during an active period in a frame period, and data lines. Voltage polarities of the data lines for all the blank period are respectively identical with voltage polarities of the data lines during the active period. A first level voltage applied to one of the data lines during all the blank period is related to an average value or a maximum value of level voltages of a portion or all of the data lines during the active period. A time length of the blank period in the frame period with the average value or the maximum value applied to one of the data lines during all the blank period is longer than a first time length of a first blank period in a first frame period adjacent to the frame period.

Abstract: A method of inhibiting and/or reducing the activity, signaling, and/or function of leukocyte-common antigen related (LAR) family of phosphatases in a cell of a subject induced by proteoglycans includes administering to the cell a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of the LAR family phosphatases without inhibiting binding to or activation the LAR family phosphatases by the proteoglycans.

Abstract: A display driving method and a display device are provided. The display driving method includes following steps: obtaining frame data of a current frame; driving a first pixel according to a first grayscale value corresponding to the first pixel in the frame data; determining whether a second grayscale value corresponding to a second pixel in the frame data is significantly different from the first grayscale value corresponding to the first pixel; obtaining a new second grayscale value when the second grayscale value is significantly different from the first grayscale value; and driving the second pixel according to the new second grayscale value. The display driving method and display device of the disclosure may achieve good display effects.

Abstract: A multihull module is provided. The multihull module includes multiple power floats, an actuation interface controller, and a vehicle controller. The power floats are disposed on a vehicle. The actuation interface controller is coupled to the power floats, and is configured to control the power floats. The vehicle controller is coupled to the actuation interface controller, and is configured to provide a control signal to the actuation interface controller. The actuation interface controller controls the power floats according to the control signal.

Abstract: The present invention is directed to a hemostatic material comprising a compacted, hemostatic aggregates of cellulosic fibers. In some aspects, the hemostatic material further includes additives, such as carboxymethyl cellulose (CMC) or other polysaccharides, calcium salts, anti-infective agents, hemostasis promoting agents, gelatin, collagen, or combinations thereof. In another aspect, the present invention is directed to a method of making the hemostatic materials described above by compacting a cellulosic-based material into hemostatic aggregates. In another aspect, the present invention is directed to a method of treating a wound by applying hemostatic materials described above onto and/or into the wound of a patient.

Abstract: The present invention is directed to compressed hemostatic tablets or forms comprising a fibrous non-woven oxidized cellulose (OC or ORC) multilayer material compressed into a form stable tablet, further comprising calcium salt, with the tablets rapidly expandable on contact with blood or blood plasma. The compressed forms may further comprise a multi-arm PEG-SG and are dimensionally, preferably with regard to length and width, stable for at least 48 hours after compression. In some embodiments, the compressed forms will expand upon contact with blood from 1.5 to 5 times of tablet length in 5 seconds; from 2 to 6 times of tablet length in 20 seconds; and from 3 to 6 times of tablet length in 5 minutes. The compressed forms are effective in hemostasis in heparinized blood.

Abstract: An electronic device includes a display unit, a voltage generation unit, a grayscale adjustment unit, and an overdriving unit. The display unit has a relationship curve between the transmittance and the driving voltage. The relationship curve has a predetermined voltage value corresponding to the maximum transmittance. The voltage generation unit generates a first voltage according to a first grayscale, and generates a second voltage according to a second grayscale. The grayscale adjustment unit receives a first display grayscale value, and outputs the second grayscale value when the first display grayscale value is equal to the first grayscale. The overdriving unit overdrives the second voltage corresponding to the second grayscale to obtain a first target driving voltage, and it provides the first target driving voltage to the display unit.

Abstract: The present invention is directed to a hemostatic material comprising a compacted, hemostatic aggregates of cellulosic fibers. In some aspects, the hemostatic material further includes additives, such as carboxymethyl cellulose (CMC) or other polysaccharides, calcium salts, anti-infective agents, hemostasis promoting agents, gelatin, collagen, or combinations thereof. In another aspect, the present invention is directed to a method of making the hemostatic materials described above by compacting a cellulosic-based material into hemostatic aggregates. In another aspect, the present invention is directed to a method of treating a wound by applying hemostatic materials described above onto and/or into the wound of a patient.

Abstract: The present invention is directed to a hemostatic semi-solid paste material comprising a bioabsorbable carrier hemostatic material; and a supplemental hemostatic agent; wherein the paste material has an elongated form extending along a lengthwise axis with an aspect ratio of at least 3; wherein the paste is self-supporting and syringe extrudable; and wherein the supplemental hemostatic agent has a non-homogenous distribution profile across a cross-section taken across the lengthwise axis. In another aspect, the present invention relates to devices for forming and expressing the hemostatic material.

Abstract: An electronic device includes gate lines, maintained at a low level voltage during a blank period and sequentially scanned during an active period in a frame period, and data lines. Voltage polarities of the data lines for all the blank period are respectively identical with voltage polarities of the data lines during the active period. A first level voltage applied to one of the data lines during all the blank period is related to an average value or a maximum value of level voltages of a portion or all of the data lines during the active period. A time length of the blank period in the frame period with the average value or the maximum value applied to one of the data lines during all the blank period is longer than a first time length of a first blank period in a first frame period adjacent to the frame period.

Abstract: A method of inhibiting and/or reducing the activity, signaling, and/or function of leukocyte-common antigen related (LAR) family of phosphatases in a cell of a subject induced by proteoglycans includes administering to the cell a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of the LAR family phosphatases without inhibiting binding to or activation the LAR family phosphatases by the proteoglycans.

Abstract: The present invention relates to the provision of an automated system and a computer-implemented method for detecting a disease such as nasopharyngeal cancer (NPC) based upon the use of either a Fuzzy Inference (FI) system or a deep learning-fuzzy inference (DeLFI) hybrid model to analyse immunofluorescence assay (IFA) images. For NPC detection, the system and method of the invention would distinguish between Epstein Barr Virus (EBV) Early Antigen (EA) positive and negative cells, and identify cellular patterns which are indicative of NPC. The DeLFI hybrid model requires less human evaluation and thereby has the potential to improve the scalability and accuracy of NPC detection.

Abstract: A method of inhibiting and/or reducing the activity, signaling, and/or function of leukocyte-common antigen related (LAR) family of phosphatases in a cell of a subject induced by proteoglycans includes administering to the cell a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of the LAR family phosphatases without inhibiting binding to or activation the LAR family phosphatases by the proteoglycans.

Abstract: The present invention is directed to a hemostatic patch comprising a porous substrate and at least a pair of co-reactive polymer reagents comprising at least one nucleophilic polyalkylene oxide based component and at least one electrophilic polyalkylene oxide-based on the porous substrate in a molar ratio of about 0.2 to about 0.9:1 of primary nucleophilic groups in excess to available electrophilic groups. The present invention is also directed to processes for the manufacture and use of such hemostatic patches.

Abstract: A method for managing HDD expanders in a cluster storage system is provided. The method according to one embodiment is implemented by each HDD expander connected indirectly to a host computer, and includes: indicating a device type not of HDD expander to the host computer when a device-type request originates from the host computer; and indicating a device type of HDD expander to a node that initiates the device-type request when otherwise.

Abstract: A method for managing HDD expanders in a cluster storage system is provided. The method according to one embodiment is implemented by each of the HDD expanders, and includes: indicating a device type of HDD expander to a parent node thereof when a device-type request originates from the parent node; and indicating a device type not of HDD expander to the parent node otherwise. The method according to another embodiment is implemented by each HDD expander connected indirectly to a root node, and includes: indicating a device type not of HDD expander to the root node when a device-type request originates from the root node; and indicating a device type of HDD expander to a node that initiates the device-type request otherwise.

Abstract: The present invention is directed to a hemostatic material comprising a compacted, hemostatic aggregates of cellulosic fibers. In some aspects, the hemostatic material further includes additives, such as carboxymethyl cellulose (CMC) or other polysaccharides, calcium salts, anti-infective agents, hemostasis promoting agents, gelatin, collagen, or combinations thereof. In another aspect, the present invention is directed to a method of making the hemostatic materials described above by compacting a cellulosic-based material into hemostatic aggregates. In another aspect, the present invention is directed to a method of treating a wound by applying hemostatic materials described above onto and/or into the wound of a patient.